CART123 Cells + Ruxolitinib for AML
(CART123 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment for individuals with acute myeloid leukemia (AML) that hasn't responded to other treatments or has recurred. It examines the safety and effectiveness of a special cell therapy called CART123, used alone or with another medication, ruxolitinib (a JAK inhibitor). The trial divides participants into two groups: one receives only CART123, while the other receives CART123 with ruxolitinib. Ideal participants are young individuals who have experienced multiple AML relapses or haven't responded to previous treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you must stop taking your current medications. However, you cannot use systemic steroids or immunosuppressants at the time of cell infusion or collection, unless they are for disease treatment at other times. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
In a previous study, CART123 cells showed promise in treating relapsed or hard-to-treat acute myeloid leukemia (AML). Research suggests these cells can locate and destroy leukemia cells. However, some patients experienced side effects, though the specifics are not always clear.
Regarding ruxolitinib, studies have found it generally well-tolerated by AML patients. Most people did not experience severe side effects, with only a few facing more serious health issues. Ruxolitinib has been safely used with other AML treatments, indicating it can be a reliable part of a treatment plan.
Both treatments have demonstrated potential in earlier research, but the combination of CART123 cells and ruxolitinib is still under study for safety and effectiveness. Researchers will closely monitor trial participants to ensure their well-being.12345Why are researchers excited about this trial's treatments?
Researchers are excited about CART123 cells combined with ruxolitinib for treating acute myeloid leukemia (AML) because of their unique approach. Unlike traditional chemotherapy, which targets rapidly dividing cells indiscriminately, CART123 cells are designed to specifically target and destroy cancer cells expressing the CD123 protein. This precision could potentially reduce collateral damage to healthy cells. In Cohort A, CART123 cells are used after chemotherapy with dose escalation, offering a tailored response. Meanwhile, in Cohort B, the addition of ruxolitinib, a JAK inhibitor, aims to enhance the anti-cancer effects by modulating the immune environment, showing promise in improving outcomes for patients with AML.
What evidence suggests that this trial's treatments could be effective for AML?
Studies have shown that CART123 cells can help about 25% of adults with relapsed or hard-to-treat acute myeloid leukemia (AML) respond positively to treatment. These cells are specially designed to find and destroy cancer cells with a marker called CD123. In this trial, participants in Cohort A will receive CART123 cells following lymphodepleting chemotherapy. Meanwhile, Cohort B will receive a combination of CART123 cells and ruxolitinib, which treats certain blood disorders, following lymphodepleting chemotherapy. Research suggests that this combination might enhance the effectiveness of CART123 by overcoming resistance in AML. These treatments are under study because they could significantly improve the survival and recovery of patients with challenging cases of AML.12345
Who Is on the Research Team?
Lucy Cain, MBBS
Principal Investigator
Children's Hospital of Philadelphia
Stephan Grupp, MD, PhD
Principal Investigator
Children's Hospital of Philadelphia
Are You a Good Fit for This Trial?
This trial is for children and young adults (up to 29 years old) with acute myeloid leukemia that has come back or not responded to treatment. Participants need good organ function, a stem cell donor available, and must not be pregnant, breastfeeding, have active infections like hepatitis or HIV, or require ongoing steroids.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepleting Chemotherapy
Participants receive lymphodepleting chemotherapy prior to CART123 infusion
Treatment
Cohort A: Dose escalation of CART123 cells; Cohort B: Fixed dose of CART123 cells with ruxolitinib
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CART123 Cells
- Ruxolitinib
Trial Overview
The study tests CART123 cells (a type of modified immune cell therapy) alone versus in combination with ruxolitinib. Participants are randomly assigned to one of the two groups to see which approach is safer and more effective for relapsed/refractory AML.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
In Cohort B, the treatment regimen will consist of lymphodepleting chemotherapy and ruxolitinib followed by a fixed dose of CART123 cells and age and body surface area-adjusted dose of ruxolitinib.
In Cohort A, the treatment regimen will consist of lymphodepleting chemotherapy followed by CART123 infusion with planned dose escalation.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stephan Grupp MD PhD
Lead Sponsor
Children's Hospital of Philadelphia
Collaborator
Citations
1.
ashpublications.org
ashpublications.org/blood/article/146/Supplement%201/1643/554185/CD123-directed-chimeric-antigen-receptor-T-cellCD123-directed chimeric antigen receptor T-cell (CART123 ...
Investigation of an autologous 4-1BB CD123-directed CAR (CART123) in adults with r/r AML yielded responses in 25% (PMID 39333315). We now report ...
CD123-directed chimeric antigen receptor T-cell ...
Investigation of an autologous 4-1BB CD123-directed CAR (CART123) in adults with r/r AML yielded responses in 25% (PMID 39333315). We now report ...
CYTOKINE-MEDIATED CAR T THERAPY RESISTANCE IN AML
Here we report a pilot study of autologous anti-CD123 CAR T cells in 12 adults with relapsed or refractory AML. CART cells targeting CD123+ cells were ...
Transduced T Cells (CART123) for the Treatment of ...
These changed cells are called CART123 cells. Giving CART123 cells may kill more tumor cells in patients with relapsed or refractory acute myeloid leukemia.
NCT04014881 | Safety and Efficacy of Anti-CD123 CAR-T ...
This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of anti-CD123 CAR-T cells in patients with refractory/relapsed CD123+ ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.